EBC-46

Intratumoral Drug Approvals: The Unique Regulatory Challenges Facing EBC-46

Intratumoral drugs like tigilanol tiglate must satisfy regulatory requirements that conventional systemic cancer therapies were never designed to address — from injection site assessment to lesion-level endpoints.

EBC-46

Energy, Inflammation, and Systemic Wellbeing: The Blushwood Berry Extract Testimonial Pattern

Across dozens of verified buyer accounts, a consistent pattern emerges: reduced inflammation, increased energy, and improved systemic wellbeing — observations that align remarkably with what we know about PKC signalling biology.

EBC-46

Indoor Cultivation of Fontainea picrosperma: What Growers Beyond Queensland Have Learned

While Fontainea picrosperma grows wild only in north Queensland's rainforests, cultivators in controlled indoor environments across Australia and Asia are proving the species thrives well beyond its native range.

EBC-46

Head and Neck Squamous Cell Carcinoma and EBC-46: What the Phase II Data Reveals

Phase II trials targeting cutaneous head and neck squamous cell carcinoma with intratumoral tigilanol tiglate show measurable responses in accessible lesions and a well-characterised safety profile.

EBC-46

The Immune Cascade After PKC Activation: How EBC-46 Recruits Neutrophils, Macrophages, and T-Cells

EBC-46 triggers a precisely ordered immune cascade — neutrophil infiltration within hours, macrophage cleanup within days, and adaptive T-cell memory that may prevent recurrence.

EBC-46

EMA PRIME Designation: How Europe's Priority Medicines Programme Could Fast-Track EBC-46

The EMA's PRIME programme offers accelerated assessment and early dialogue for promising cancer therapies. Here is what that pathway could mean for tigilanol tiglate.

EBC-46

Stage 4 Cancer and Blushwood Extract: The Patient Accounts That Demand Attention

Some of the most striking verified reports come from people facing stage 4 cancer diagnoses who began taking blushwood berry extract. These accounts are anecdotal — but they are also scientifically coherent.

EBC-46

The Unmapped Phytochemistry of the Blushwood Berry: What Science Has Not Yet Studied

Tigilanol tiglate gets all the scientific attention, but it is one compound within a chemically complex plant. The unmapped phytochemistry of Fontainea picrosperma may hold compounds we have not yet imagined.

EBC-46

Biomarker Endpoints in EBC-46 Clinical Research: What Researchers Are Measuring and Why

The biomarkers chosen for EBC-46 trials are not arbitrary — they reflect the current scientific understanding of how tigilanol tiglate kills tumours. Here's what researchers are measuring and why it matters.

EBC-46

Diacylglycerol Mimicry: Why EBC-46 Binds Protein Kinase C With Unusual Selectivity

EBC-46 doesn't force its way into cells — it speaks their language. By mimicking diacylglycerol, the compound activates PKC with a precision that synthetic drugs rarely achieve. Here's the molecular story.

EBC-46

Compassionate Use and Expanded Access: What They Mean for Tigilanol Tiglate Patients

Before a drug achieves full approval, compassionate use and expanded access programmes can provide a legal pathway for patients who have no other options. Here's how they apply to tigilanol tiglate.

EBC-46

How to Dose Blushwood Berry Extract: A Practical Guide to EBC-46 Supplementation

Supplement manufacturers have developed EBC-46 dosing protocols based on formulation research and real-world feedback. Here's what the data suggests about when and how to take it.